|
Calderasib Clinical Trials
7 actively recruiting trials across 6 locations
▲ +1 trial since June 2026
Also known as: MK-1084
Pipeline
Phase 1: 1Phase 2: 1Phase 3: 5
Top Sponsors
- Merck Sharp & Dohme LLC7
Indications
- Cancer7
- Lung Cancer4
- Non Small Cell Lung Cancer4
- Neoplasm Malignant1
- Rectal Adenocarcinoma1
Other1 trial
Birmingham, Alabama1 trial
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Central Alabama Research ( Site 0108)
Phase 3
Bakersfield, California1 trial
Los Angeles, California1 trial
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Los Angeles Hematology Oncology Medical Group ( Site 0084)
Phase 3
Tampa, Florida1 trial
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Moffitt Cancer Center ( Site 0261)
Phase 1
Baltimore, Maryland1 trial
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Greater Baltimore Medical Center ( Site 1104)
Phase 2
Lincoln, Nebraska1 trial
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NHO Revive Research Institute LLC ( Site 0118)
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.